TABLE 3 .

] Assessment of Feasibility and Relevance of Quality Indicators

	Site 1			Site 2			Site 3
Quality Indicator	NR, %	Yes, %	Timea	NR, %	Yes, %	Timea	NR, %	Yes, %	Timea
1. Percentage of nonsurgical biopsies in patients with clinical stage IV nonsquamous lung cancer who obtained an adequate amount of tissue for molecular testing	81	89.5	1.18	82	72.2	2.48	84	62.5	3.13
2. Percentage of patients with clinical stage III or IV lung cancer, or neurologic symptoms, who have had brain imaging performed within 3 mo of the initiation of treatment	48	96.2	1.14	46	96.3	2.21	49	88.2	3.5
3. Percentage of patients with evidence of one to three distant metastases who have had an attempt at biopsy confirmation of a site of metastasis, or documentation of a reason that this was not possible or necessary	82.5	62.9	1.16	80	50	2.11	67	97.0	3.16
4. Percentage of patients with clinical stage IB or higher, but no evidence of metastatic disease, who have had a mediastinal lymph node sampling procedure performed prior to the initiation of curative-intent therapy	47.5	95.2	1.24	43.5	96.5	2.11	64	80.6	3.21
5. Percentage of patients with lung cancer who have an AJCC seventh edition clinical lung cancer stage documented prior to curative-intent therapy	24.5	58.3	1.61	24.5	61.6	1.98	16	76.2	3.77
6. Percentage of active smokers with lung cancer who have had smoking cessation counseling documented	74.5	70.6	1.20	81.5	59.5	1.74	76	75	3.15
7. Percentage of patients with lung cancer in whom a performance status measure is documented in the pretreatment phase	0	100	1.01	0	71	1.54	1	88.9	4.21

Two hundred patients were reviewed at site 1 and site 2, 100 at site 3. NR = not relevant. See Table 1 legend for expansion of other abbreviation.

^aTime scale is 1 = very easy (< 1-min search), 5 = neither easy nor hard (approximately 15-min search), 9 = very difficult (> 30-min search).